Identification of HLA-DRB1 association to adalimumab immunogenicity.
Anti-drug antibody formation occurs with most biological agents across disease states, but the mechanism by which they are formed is unknown. The formation of anti-drug antibodies to adalimumab (AAA) may decrease its therapeutic effects in some patients. HLA alleles have been reported to be associat...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5882140?pdf=render |
id |
doaj-54e61afa36b242ac93a2c3be0dc93e35 |
---|---|
record_format |
Article |
spelling |
doaj-54e61afa36b242ac93a2c3be0dc93e352020-11-25T02:05:56ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01134e019532510.1371/journal.pone.0195325Identification of HLA-DRB1 association to adalimumab immunogenicity.Mohan LiuJacob DegnerJustin Wade DavisKenneth B IdlerAhmed NaderNael M MostafaJeffrey F WaringAnti-drug antibody formation occurs with most biological agents across disease states, but the mechanism by which they are formed is unknown. The formation of anti-drug antibodies to adalimumab (AAA) may decrease its therapeutic effects in some patients. HLA alleles have been reported to be associated with autoantibody formation against interferons and other TNF inhibitors, but not adalimumab. We analyzed samples from 634 subjects with either rheumatoid arthritis (RA) or hidradenitis suppurativa (HS): 37 subjects (17 RA and 20 HS) developed AAA (AAA+) during adalimumab treatment and 597 subjects (348 RA, 249 HS) did not develop AAA (AAA-) during the clinical trials. Using next-generation sequencing-based HLA typing, we identified three protective HLA alleles (HLA-DQB1*05, HLA-DRB1*01,and HLA-DRB1*07) that were less prevalent in AAA+ than AAA-subjects (ORs: 0.4, 0.25 and 0.28, respectively; and P values: 0.012, 0.012 and 0.018, respectively) and two risk HLA alleles (HLA-DRB1*03 and HLA-DRB1*011) that were more abundant in AAA+ than AAA-subjects (ORs: 2.52, and 2.64, respectively; and P values: 0.006 and 0.019). Similar to the finding of Billiet et al. who found that carriage of the HLA-DRB1*03 allele was more prevalent in those with anti-infliximab antibodies (OR = 3.6, p = 0.002, 95% CI: [1.5,8.6]).), we found HLA-DRB1*03 allele was also more prevalent in anti-adalimumab positive (OR = 2.52, p = 0.006, 95% CI: [1.37,4.63]). The results suggest that specific HLA alleles may play a key role in developing AAAs in RA and HS patients treated with adalimumab.http://europepmc.org/articles/PMC5882140?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mohan Liu Jacob Degner Justin Wade Davis Kenneth B Idler Ahmed Nader Nael M Mostafa Jeffrey F Waring |
spellingShingle |
Mohan Liu Jacob Degner Justin Wade Davis Kenneth B Idler Ahmed Nader Nael M Mostafa Jeffrey F Waring Identification of HLA-DRB1 association to adalimumab immunogenicity. PLoS ONE |
author_facet |
Mohan Liu Jacob Degner Justin Wade Davis Kenneth B Idler Ahmed Nader Nael M Mostafa Jeffrey F Waring |
author_sort |
Mohan Liu |
title |
Identification of HLA-DRB1 association to adalimumab immunogenicity. |
title_short |
Identification of HLA-DRB1 association to adalimumab immunogenicity. |
title_full |
Identification of HLA-DRB1 association to adalimumab immunogenicity. |
title_fullStr |
Identification of HLA-DRB1 association to adalimumab immunogenicity. |
title_full_unstemmed |
Identification of HLA-DRB1 association to adalimumab immunogenicity. |
title_sort |
identification of hla-drb1 association to adalimumab immunogenicity. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2018-01-01 |
description |
Anti-drug antibody formation occurs with most biological agents across disease states, but the mechanism by which they are formed is unknown. The formation of anti-drug antibodies to adalimumab (AAA) may decrease its therapeutic effects in some patients. HLA alleles have been reported to be associated with autoantibody formation against interferons and other TNF inhibitors, but not adalimumab. We analyzed samples from 634 subjects with either rheumatoid arthritis (RA) or hidradenitis suppurativa (HS): 37 subjects (17 RA and 20 HS) developed AAA (AAA+) during adalimumab treatment and 597 subjects (348 RA, 249 HS) did not develop AAA (AAA-) during the clinical trials. Using next-generation sequencing-based HLA typing, we identified three protective HLA alleles (HLA-DQB1*05, HLA-DRB1*01,and HLA-DRB1*07) that were less prevalent in AAA+ than AAA-subjects (ORs: 0.4, 0.25 and 0.28, respectively; and P values: 0.012, 0.012 and 0.018, respectively) and two risk HLA alleles (HLA-DRB1*03 and HLA-DRB1*011) that were more abundant in AAA+ than AAA-subjects (ORs: 2.52, and 2.64, respectively; and P values: 0.006 and 0.019). Similar to the finding of Billiet et al. who found that carriage of the HLA-DRB1*03 allele was more prevalent in those with anti-infliximab antibodies (OR = 3.6, p = 0.002, 95% CI: [1.5,8.6]).), we found HLA-DRB1*03 allele was also more prevalent in anti-adalimumab positive (OR = 2.52, p = 0.006, 95% CI: [1.37,4.63]). The results suggest that specific HLA alleles may play a key role in developing AAAs in RA and HS patients treated with adalimumab. |
url |
http://europepmc.org/articles/PMC5882140?pdf=render |
work_keys_str_mv |
AT mohanliu identificationofhladrb1associationtoadalimumabimmunogenicity AT jacobdegner identificationofhladrb1associationtoadalimumabimmunogenicity AT justinwadedavis identificationofhladrb1associationtoadalimumabimmunogenicity AT kennethbidler identificationofhladrb1associationtoadalimumabimmunogenicity AT ahmednader identificationofhladrb1associationtoadalimumabimmunogenicity AT naelmmostafa identificationofhladrb1associationtoadalimumabimmunogenicity AT jeffreyfwaring identificationofhladrb1associationtoadalimumabimmunogenicity |
_version_ |
1724935982805942272 |